Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Cash from Operations (2019 - 2025)

Nurix Therapeutics (NRIX) has disclosed Cash from Operations for 7 consecutive years, with 67832000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Cash from Operations fell 39.14% to 67832000.0 in Q4 2025 year-over-year; TTM through Nov 2025 was 249465000.0, a 44.55% decrease, with the full-year FY2025 number at 249465000.0, down 44.55% from a year prior.
  • Cash from Operations was 67832000.0 for Q4 2025 at Nurix Therapeutics, down from 57385000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 26689000.0 in Q4 2023 to a low of 67832000.0 in Q4 2025.
  • A 5-year average of 37379300.0 and a median of 41542000.0 in 2023 define the central range for Cash from Operations.
  • Peak YoY movement for Cash from Operations: crashed 629.37% in 2022, then soared 170.32% in 2023.
  • Nurix Therapeutics' Cash from Operations stood at 30911000.0 in 2021, then fell by 22.79% to 37955000.0 in 2022, then skyrocketed by 170.32% to 26689000.0 in 2023, then plummeted by 282.66% to 48751000.0 in 2024, then plummeted by 39.14% to 67832000.0 in 2025.
  • Per Business Quant, the three most recent readings for NRIX's Cash from Operations are 67832000.0 (Q4 2025), 57385000.0 (Q3 2025), and 63161000.0 (Q2 2025).